In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), ...
Accuray Incorporated ( NASDAQ: ARAY) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback